U.S. Markets open in 34 mins

Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Crocs, Inc. (CROX), Portola Pharmaceuticals, Inc. (PTLA), ANSYS, Inc. (ANSS), Alpha and Omega Semiconductor Limited (AOSL), PetMed Express, Inc. (PETS), and MYOS RENS Technology Inc. (MYOS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CROX DOWNLOAD: http://Capital-Review.com/register/?so=CROX
PTLA DOWNLOAD: http://Capital-Review.com/register/?so=PTLA
ANSS DOWNLOAD: http://Capital-Review.com/register/?so=ANSS
AOSL DOWNLOAD: http://Capital-Review.com/register/?so=AOSL
PETS DOWNLOAD: http://Capital-Review.com/register/?so=PETS
MYOS DOWNLOAD: http://Capital-Review.com/register/?so=MYOS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Crocs, Inc. (CROX), Portola Pharmaceuticals, Inc. (PTLA), ANSYS, Inc. (ANSS), Alpha and Omega Semiconductor Limited (AOSL), PetMed Express, Inc. (PETS), and MYOS RENS Technology Inc. (MYOS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CROCS, INC. (CROX) REPORT OVERVIEW

Crocs' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Crocs reported revenue of $261.06MM vs $243.27MM (up 7.31%) and analysts estimated basic earnings per share $0.08 vs -$0.03. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Crocs reported revenue of $1,023.51MM vs $1,036.27MM (down 1.23%) and analysts estimated basic earnings per share -$0.07 vs -$0.43. Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.41. The estimated EPS forecast for the next fiscal year is $1.05 and is expected to report on February 28th, 2019.

To read the full Crocs, Inc. (CROX) report, download it here: http://Capital-Review.com/register/?so=CROX

-----------------------------------------

PORTOLA PHARMACEUTICALS, INC. (PTLA) REPORT OVERVIEW

Portola Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Portola Pharmaceuticals reported revenue of $14.18MM vs $3.83MM (up 270.35%) and analysts estimated basic earnings per share -$1.08 vs -$1.41. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Portola Pharmaceuticals reported revenue of $22.55MM vs $35.50MM (down 36.50%) and analysts estimated basic earnings per share -$4.81 vs -$4.76. Analysts expect earnings to be released on March 1st, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$1.41. The estimated EPS forecast for the next fiscal year is -$3.82 and is expected to report on March 1st, 2019.

To read the full Portola Pharmaceuticals, Inc. (PTLA) report, download it here: http://Capital-Review.com/register/?so=PTLA

-----------------------------------------

ANSYS, INC. (ANSS) REPORT OVERVIEW

ANSYS's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, ANSYS reported revenue of $289.42MM vs $275.59MM (up 5.02%) and analysts estimated basic earnings per share $1.06 vs $0.87 (up 21.84%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ANSYS reported revenue of $1,095.25MM vs $988.47MM (up 10.80%) and analysts estimated basic earnings per share $3.05 vs $3.05 (unchanged). Analysts expect earnings to be released on February 27th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.97. The estimated EPS forecast for the next fiscal year is $4.75 and is expected to report on February 27th, 2019.

To read the full ANSYS, Inc. (ANSS) report, download it here: http://Capital-Review.com/register/?so=ANSS

-----------------------------------------

ALPHA AND OMEGA SEMICONDUCTOR LIMITED (AOSL) REPORT OVERVIEW

Alpha and Omega Semiconductor's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Alpha and Omega Semiconductor reported revenue of $114.93MM vs $103.90MM (up 10.62%) and basic earnings per share -$0.06 vs $0.28. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Alpha and Omega Semiconductor reported revenue of $421.55MM vs $383.34MM (up 9.97%) and analysts estimated basic earnings per share $0.60 vs $0.59 (up 1.69%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $0.51 and is expected to report on August 14th, 2019.

To read the full Alpha and Omega Semiconductor Limited (AOSL) report, download it here: http://Capital-Review.com/register/?so=AOSL

-----------------------------------------

PETMED EXPRESS, INC. (PETS) REPORT OVERVIEW

PetMed Express' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, PetMed Express reported revenue of $60.07MM vs $60.11MM (down 0.07%) and analysts estimated basic earnings per share $0.38 vs $0.45 (down 15.56%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, PetMed Express reported revenue of $273.80MM vs $249.18MM (up 9.88%) and analysts estimated basic earnings per share $1.83 vs $1.18 (up 55.08%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full PetMed Express, Inc. (PETS) report, download it here: http://Capital-Review.com/register/?so=PETS

-----------------------------------------

MYOS RENS TECHNOLOGY INC. (MYOS) REPORT OVERVIEW

MYOS RENS Technology's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, MYOS RENS Technology reported revenue of $0.07MM vs $0.16MM (down 58.75%) and analysts estimated basic earnings per share -$0.12 vs -$0.13. For the twelve months ended December 31st, 2017 vs December 31st, 2016, MYOS RENS Technology reported revenue of $0.53MM vs $0.33MM (up 60.86%) and analysts estimated basic earnings per share -$0.69 vs -$0.90. Analysts expect earnings to be released on March 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$0.52 and is expected to report on March 26th, 2019.

To read the full MYOS RENS Technology Inc. (MYOS) report, download it here: http://Capital-Review.com/register/?so=MYOS

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.